Global Medical-grade Perfluorobutylpentane Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Medical-grade Perfluorobutylpentane market size was valued at US$ 28.60 million in 2025 and is forecast to a readjusted size of US$ 50.96 million by 2032 with a CAGR of 8.0% during review period.
Medical-grade perfluorobutylpentane, commonly referred to as F4H5, is a clear and colorless semifluorinated alkane composed of a perfluorobutyl segment and a pentyl segment. Its low surface tension, strong spreading properties, amphiphilic character, and ability to dissolve silicone oil and selected lipophilic drugs make it suitable primarily as a water-free ophthalmic drug-delivery vehicle and as a sterile medical liquid for removing silicone oil residues and cleaning intraocular lenses during vitreoretinal procedures. Key upstream inputs include high-purity fluorinated organic intermediates, carbon-chain coupling materials, high-purity solvents and process gases, together with distillation and purification capacity, trace-impurity control, sterile filtration, cleanroom filling, and pharmaceutical packaging components. Major downstream customers include ophthalmic pharmaceutical companies, ophthalmic medical-device manufacturers, sterile drug-product CDMOs, hospitals, and specialist eye centers. Under the narrow medical-material scope, estimated global effective capacity was approximately 2,600 kg/yr in 2025, while sales volume was approximately 1,763 kg, corresponding to capacity utilization of about 67.8%. The weighted average ex-factory price was approximately USD 15,768 per kg, and the typical industry gross margin ranged from 40% to 60%.
The global medical-grade perfluorobutylpentane market remains a highly specialized ophthalmic materials segment characterized by a small number of qualified suppliers, a limited commercial product portfolio, and substantial technical and regulatory barriers. Current commercial demand is concentrated in two principal routes: pure F4H5 surgical washout liquids and water-free cyclosporine ophthalmic solutions. The value chain is divided among technology owners, raw-material suppliers, sterile formulation manufacturers, CDMOs, marketing authorization holders, and commercial distributors. The synthesis process, impurity profile, and pharmaceutical quality documentation for F4H5 are generally confidential, and changing the excipient source in an approved drug may require additional quality, stability, and regulatory comparability work. Suppliers already qualified within approved ophthalmic products therefore benefit from meaningful switching barriers and durable customer relationships. The principal demand driver is the geographic expansion of water-free ophthalmic drug-delivery technology. F4H5 can dissolve hydrophobic compounds such as cyclosporine and enables a clear, non-aqueous ophthalmic solution without conventional surfactants or antimicrobial preservatives. VEVYE is commercially available in the United States, Vevizye has been approved in the European Union, and Heng Yi received approval in China in 2026. These developments are shifting F4H5 from a narrowly used vitreoretinal surgical material toward a pharmaceutical excipient with commercial demand across several major healthcare markets. Future growth will depend primarily on prescription adoption, European and Chinese launches, and the ability of EyeSol-type platforms to deliver additional lipophilic ophthalmic drugs, rather than solely on growth in silicone-oil removal procedures. Technology development will increasingly focus on high-purity manufacturing, control of fluorinated process impurities, extremely low moisture levels, sterility assurance, and compatibility with primary packaging rather than on nominal assay alone. The FDA quality review of the F4H5-containing cyclosporine product addressed identity, related substances, visible and sub-visible particles, sterility, and extractables and leachables from the container-closure system, demonstrating that commercialization requires integrated development of the material, formulation, filling process, and packaging. F4H5 may also be evaluated as a carrier for tacrolimus, anti-inflammatory agents, glaucoma therapies, and other poorly water-soluble ophthalmic compounds. However, translation from laboratory research to commercial products will require formulation stability, ocular tolerability, long-term safety, and scalable non-aqueous sterile filling. CDMOs combining analytical, sterile manufacturing, and ophthalmic packaging capabilities are therefore expected to become increasingly important. Major constraints include the small overall demand base, concentrated supply, limited transparency regarding excipient sourcing, long pharmaceutical development timelines, and increasing scrutiny of environmentally persistent fluorinated substances. The EMA concluded that available non-clinical data did not indicate a particular human safety hazard from the perfluorobutylpentane excipient, but its environmental assessment identified a potential for persistence. Future requirements covering manufacturing emissions, waste-liquid management, product disposal, and fluorinated-substance regulation may therefore increase compliance costs. F4H5-based products must also compete with conventional cyclosporine emulsions, alternative anti-inflammatory eye drops, and other dry-eye treatment mechanisms. The market is consequently more likely to expand steadily around a small number of high-value ophthalmic applications than to develop into a high-volume commodity chemical sector, favoring suppliers with complete regulatory documentation, secure long-term supply, and credible environmental management systems.
This report is a detailed and comprehensive analysis for global Medical-grade Perfluorobutylpentane market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Medical-grade Perfluorobutylpentane market size and forecasts, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/kg), 2021-2032
Global Medical-grade Perfluorobutylpentane market size and forecasts by region and country, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/kg), 2021-2032
Global Medical-grade Perfluorobutylpentane market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/kg), 2021-2032
Global Medical-grade Perfluorobutylpentane market shares of main players, shipments in revenue ($ Million), sales quantity (kg), and ASP (US$/kg), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Medical-grade Perfluorobutylpentane
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Medical-grade Perfluorobutylpentane market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Geuder, Siegfried, HWI Group, Hengrui Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Medical-grade Perfluorobutylpentane market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Pharmaceutical Excipient Grade
Sterile Surgical Grade
Other
Market segment by Product Form
Bulk Liquid
Sterile Single-use Vial
Other
Market segment by Application
Ophthalmic Pharmaceutical Companies
Pharmaceutical CDMOs
Other
Major players covered
Geuder
Siegfried
HWI Group
Hengrui Pharma
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Medical-grade Perfluorobutylpentane product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Medical-grade Perfluorobutylpentane, with price, sales quantity, revenue, and global market share of Medical-grade Perfluorobutylpentane from 2021 to 2026.
Chapter 3, the Medical-grade Perfluorobutylpentane competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Medical-grade Perfluorobutylpentane breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Medical-grade Perfluorobutylpentane market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Medical-grade Perfluorobutylpentane.
Chapter 14 and 15, to describe Medical-grade Perfluorobutylpentane sales channel, distributors, customers, research findings and conclusion.